Actively Recruiting

Phase 3
Age: 18Years - 75Years
All Genders
NCT07339111

Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis

Led by Medipost, Inc. · Updated on 2026-05-08

300

Participants Needed

16

Research Sites

172 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

To establish the efficacy and safety of CARTISTEM®, a combination product composed of allogeneic human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) formulated with a cross-linked sodium hyaluronate (HA) hydrogel, CARTISTEM® compared to the surgical comparator of debridement in Subjects with knee cartilage lesions and osteoarthritis. This trial is intended to provide evidence of the superiority of CARTISTEM® to reduce knee pain and improve knee function compared to debridement for Subjects with knee cartilage lesions and osteoarthritis at 2-years post-treatment. Additionally, this trial is intended to intended to explore whether CARTISTEM® may have disease-modifying effects on osteoarthritis progression through the use of semi-quantitative MRI assessment.

CONDITIONS

Official Title

Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 to 75 years old
  • Diagnosed knee osteoarthritis in the affected knee per American College of Rheumatology guidelines
  • Failed conservative knee osteoarthritis treatments for at least 3 months
  • Kellgren-Lawrence grade 2 or 3 in the affected knee
  • Femoral cartilage defects classified as Outerbridge Grade 3 or 4 with lesion area between 2 and 9 cm2, including at least one lesion 2 cm2 or larger
  • Body Mass Index (BMI) of 35 kg/m2 or less
  • Visual Analog Scale (VAS) pain score in the affected knee between 40 and 90 (100-point scale)
  • VAS pain score in the opposite knee 30 or less
  • WOMAC4 function score between 25 and 90 (100-point scale)
  • WOMAC4 pain score between 40 and 90 (100-point scale)
  • Willingness to avoid treatments in the affected knee from consent until study end
  • Willingness to discontinue analgesics except allowed rescue medication and limited NSAID use per protocol
  • Controlled blood pressure if diagnosed with stage 3 hypertension
  • Normal or clinically acceptable lab results
  • Female participants of childbearing potential must use effective birth control
  • Ability to comply with rehabilitation and study requirements
  • Ability to provide informed consent
Not Eligible

You will not qualify if you...

  • Intra-articular injection of hyaluronic acid, platelet-rich plasma, bone marrow aspirate/concentrate, steroids, or investigational drugs in either knee within 3 months before consent
  • Bone marrow lesion grade 3 outside femoral lesion area in affected knee
  • Kellgren-Lawrence grade 0, 1 or 4 in affected knee or grade 4 in opposite knee
  • Knee malalignment of 6 degrees or more in either knee
  • Joint ligament instability grade 3 or requiring surgery in affected knee
  • Complete meniscal deficiency, meniscal root tears, or severe meniscal extrusion
  • Large kissing bipolar lesions exceeding 25% of femoral lesion area or penetrating subchondral bone
  • Knee surgery within 6 months before consent or radiation therapy to affected knee
  • Chronic inflammatory joint diseases like rheumatoid arthritis, gout, fibromyalgia
  • Bone disorders such as osteonecrosis, osteochondritis dissecans, bone tumors, fractures
  • Joint infections or tumors in the affected knee
  • Certain systemic diseases including Paget's disease, acromegaly, genetic collagen disorders
  • Vascular or neurological disorders of lower limbs (varicose veins not excluded)
  • Autoimmune diseases such as Addison's disease, multiple sclerosis, lupus (celiac disease is allowed)
  • Systemic infections like HIV, hepatitis, syphilis, or blood clotting disorders
  • Use of anticoagulant medications except low-dose aspirin
  • Uncontrolled diabetes with HbA1c over 8%
  • Infectious diseases requiring IV antibiotics
  • Recent use of immunosuppressants or chemotherapy
  • Previous allogeneic stem cell therapy
  • Prior cartilage repair surgeries or knee replacements in affected knee (some exceptions)
  • Known allergy to hyaluronan
  • Pregnancy or nursing
  • Psychotic diseases, epilepsy, or recent substance/alcohol abuse
  • Contraindication to MRI or unwillingness to have MRI
  • Current litigation related to workman's compensation or disability
  • Any other reason the investigator deems unsuitable for participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 16 locations

1

Flourish Research Birmingham

Birmingham, Alabama, United States, 35205

Actively Recruiting

2

AZ Orthopedic

Tempe, Arizona, United States, 85224

Actively Recruiting

3

TriWest Research Associates

El Cajon, California, United States, 91910

Not Yet Recruiting

4

Horizon Clinical Research

La Mesa, California, United States, 91924

Not Yet Recruiting

5

Source Healthcare

Santa Monica, California, United States, 90403

Actively Recruiting

6

Orthopedic Centers of Colorado

Parker, Colorado, United States, 80134

Actively Recruiting

7

Steamboat Orthopaedic and Spine Institute

Steamboat Springs, Colorado, United States, 80487

Actively Recruiting

8

Curalta Clinical Trials

Westwood, New Jersey, United States, 07662

Actively Recruiting

9

Atrium Health Mercy

Charlotte, North Carolina, United States, 28207

Not Yet Recruiting

10

West Clinical Research

Morehead City, North Carolina, United States, 28557

Actively Recruiting

11

University of Cincinnati Department of Orthopaedic Surgery

Cincinnati, Ohio, United States, 45267

Actively Recruiting

12

Zenos Clinical Research

Dallas, Texas, United States, 75230

Actively Recruiting

13

Memorial Hermann Center

Houston, Texas, United States, 77043

Actively Recruiting

14

HD Research Corp.

Houston, Texas, United States, 77401

Actively Recruiting

15

Flourish Research San Antonio

San Antonio, Texas, United States, 78229

Actively Recruiting

16

JBR Clinical Research

Salt Lake City, Utah, United States, 84107

Actively Recruiting

Loading map...

Research Team

A

Adrian Orr, VP Clinical Development

CONTACT

L

Luis Toro, Medical Monitor for IQVIA, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here